News & insights

Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec

Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

Find Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Study of FTX-101 for the Treatment of Chronic Optic Neuropathy

Sutter Health Deploys World’s First Wearable Doppler Ultrasound Patch to Enhance Safety of ICU Patients

Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW191, A Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW171, A Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers

Zymeworks Announces China NMPA Acceptance Of Biologics License Application For Zanidatamab For Second-Line Treatment Of Biliary Tract Cancer

Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

Inversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International Conference

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

Immugenia Obtains Pre-Seed Funding from adMare BioInnovations, ACET Capital, and Sherbrooke Innopole to Develop a Cancer Treatment Which Would Prevent Relapses

adMare Portfolio Company Neurasic Therapeutics Receives New Grant to Advance Non-Opioid Pain Treatment

adMare Portfolio Company BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Bright Angel Therapeutics Announces New Funding to Advance Therapies for Invasive Fungal Infections